Frequently Asked Questions About Phage Therapy

DESCRIPTION / INFORMATION

Bacteriophages (usually simply called phages) are viruses that infect bacteria. They are found wherever bacteria live and are among the most abundant biological entities on Earth. Long before antibiotics became available, physicians and scientists experimented with phages as treatments for bacterial infections. Interest declined in much of the Western world after antibiotics became widely available, but phage therapy continued to be used in parts of Eastern Europe and the former Soviet Union.

Today, increasing antimicrobial resistance has renewed worldwide interest in phage therapy. Modern approaches combine century-old biological principles with bacterial genome sequencing, phage banks, susceptibility testing, advanced manufacturing, and clinical trials. Phage therapy remains investigational in the United States and most of Western Europe, although selected patients may receive it through clinical trials or expanded-access pathways.

These 20 questions explain how phage therapy works, where it may be useful, what its risks and limitations are, how phages are selected and manufactured, and what research is needed before phage therapy can become a more routine part of medical care.

At a Glance: Phages and Antibiotics

	Bacteriophages	Antibiotics
What are they?	Viruses that infect bacteria	Chemical or biological substances that inhibit or kill bacteria
Target range	Often very narrow—sometimes limited to certain strains	Varies from narrow to very broad
Do they infect human cells?	They do not reproduce in human cells	Not applicable
Effect on normal microbiota	Potentially more targeted, depending on host range	Broad-spectrum drugs may affect many non-target bacteria
Can bacteria become resistant?	Yes	Yes
Can activity increase at the infection site?	Sometimes; productive infection of susceptible bacteria can generate additional phages	No self-replication
Can they work in biofilms?	Some phages and phage enzymes can disrupt or penetrate biofilm components	Some antibiotics work poorly against biofilm-associated bacteria
Can they be combined?	Yes; combinations may be synergistic, additive, neutral, or occasionally antagonistic	Antibiotic combinations are also commonly used
Need organism-specific matching?	Often yes, especially for personalized therapy	Susceptibility testing is also frequently used, but empiric therapy is often possible
Routine FDA-approved therapy?	No approved human phage-therapy product in the U.S. at present	Many FDA-approved antibiotics
Current U.S. access	Clinical trials or FDA-authorized expanded access/IND pathways	Standard clinical prescribing

Phage therapy is therefore not simply a biological replacement for antibiotics. It has a different set of strengths, limitations, and practical requirements.

QUESTIONS

1. What is phage therapy?

Phage therapy is the therapeutic use of bacteriophages to treat bacterial infections.

Bacteriophages are viruses whose natural hosts are bacteria. A phage recognizes particular structures on a bacterial cell, attaches to that cell, and introduces its genetic material. Certain phages then reproduce inside the bacterium and ultimately destroy it.

Therapeutic phages are generally selected to kill the bacterial pathogen responsible for an infection.

The idea is more than a century old. Phages were discovered independently in the early 20th century, and Félix d’Hérelle began using them therapeutically soon afterward. Clinical phage use continued for decades in countries such as Georgia and Poland even as antibiotics became dominant elsewhere.

Modern interest has grown because multidrug-resistant bacteria are increasingly difficult to treat with existing antibiotics.

2. How do bacteriophages kill bacteria?

For therapeutic purposes, researchers generally favor lytic phages.

A typical lytic infection involves several steps:

1. Attachment: The phage binds to a particular receptor on the bacterial surface.
2. Entry: The phage introduces its genetic material into the bacterium.
3. Replication: The bacterial cell is redirected toward production of new phage components.
4. Assembly: New phage particles are assembled.
5. Lysis: The bacterial cell breaks open, releasing newly formed phages that may infect additional susceptible bacteria.

This specificity is one of the great strengths (and one of the major limitations) of phage therapy. A phage that kills one strain of Pseudomonas aeruginosa, for example, may fail to infect another strain of the same bacterial species.

Bacteriophages do not reproduce in human cells, although phages and phage components can interact with the human immune system.

3. What types of infections might phage therapy treat?

Phage therapy has been investigated for many difficult bacterial infections, including infections caused by:

• Pseudomonas aeruginosa;
• Staphylococcus aureus, including MRSA;
• Escherichia coli;
• Klebsiella pneumoniae;
• Acinetobacter baumannii;
• Enterococcus species;
• Burkholderia species;
• Mycobacterium species; and
• other antibiotic-resistant bacteria.

Clinical reports and trials have included:

• chronic wound infections;
• osteomyelitis and other bone or joint infections;
• prosthetic-joint and device-associated infections;
• urinary tract infections;
• bloodstream infections;
• respiratory infections;
• infections associated with cystic fibrosis;
• burns; and
• biofilm-associated infections.

However, publication of successful cases does not mean that phage therapy is established as effective for all of these conditions.

The strength of the clinical evidence varies greatly according to organism and infection type.

4. How is phage therapy different from antibiotic therapy?

The most obvious difference is specificity.

Many antibiotics act against broad groups of bacteria. A therapeutic phage often infects only one bacterial species and may attack only certain strains within that species.

This narrow host range has potential advantages. Phage treatment may have less effect on unrelated members of the patient’s microbiome than a broad-spectrum antibiotic.

Phages also have biological properties that antibiotics do not. If a phage successfully infects susceptible bacteria at an infection site, additional phage particles can be produced there.

Some phages also possess enzymes that help them interact with bacterial capsules or biofilms.

However, these advantages are not automatic.

A phage cannot reproduce where there are no susceptible bacterial hosts. The immune system may remove circulating phages. Poor tissue penetration may prevent a phage from reaching an infection. A bacterial strain may already be resistant or become resistant during treatment.

Therefore, phages and antibiotics should not be viewed simply as competing technologies. In many current treatment approaches, phages are being investigated alongside antibiotics rather than instead of them.

5. Is phage therapy safe?

Modern studies generally provide a reassuring safety picture, but the available clinical evidence remains much smaller than that for routinely approved antibiotics.

A systematic review of 16 clinical trials found that all 13 modern trials included in the review concluded that phage therapy was safe. However, the same review found much less consistent evidence of clinical efficacy. (Stacey et al., 2022)

This distinction is important: demonstrating that a treatment appears reasonably safe is not the same as demonstrating that it reliably works.

Phages themselves generally do not reproduce in human cells. Nevertheless, patients can develop immune responses to them, and rapid killing of bacteria can release bacterial inflammatory products.

The quality of the phage preparation also matters greatly. A poorly purified preparation may contain endotoxin, bacterial proteins, DNA, or other unwanted material left over from the bacteria used to grow the phages.

Modern manufacturing therefore places considerable emphasis on purification, identity, sterility, genomic characterization, potency, and control of bacterial contaminants.

6. What are the main risks or side effects of phage therapy?

Reported adverse effects have generally been limited, but several potential risks deserve attention.

These include:

• fever or inflammatory reactions;
• local irritation with topical treatment;
• immune responses against the administered phages;
• rapid removal or neutralization of phages by the immune system;
• release of bacterial inflammatory components during bacterial killing;
• contamination or excessive endotoxin in inadequately purified products;
• failure of treatment because the bacterium is not susceptible;
• development of phage-resistant bacteria; and
• undesirable bacterial genes associated with an inadequately characterized phage.

This last concern is one reason whole-genome sequencing is important. Therapeutic programs generally try to avoid phages carrying genes associated with toxins, antibiotic resistance, or other harmful functions.

Many programs also favor obligately lytic phages rather than temperate phages.

7. How is phage therapy administered?

The route depends largely on the location of the infection and the characteristics of the phage preparation.

Phages have been administered:

• intravenously for systemic or deep infections;
• topically to wounds;
• through wound irrigation;
• directly into infected cavities or surgical sites;
• by inhalation or nebulization for respiratory infections;
• orally for some gastrointestinal applications;
• into the bladder for some urinary applications; and
• by other forms of local administration.

Some patients receive phages by more than one route.

Delivery matters because phages must remain active long enough and reach sufficient numbers of susceptible bacteria at the infection site.

An effective phage in the laboratory may therefore fail clinically if it cannot reach the bacteria inside a patient’s body.

8. Is phage therapy personalized, and how are the right phages selected?

Often, yes.

One approach begins by isolating the bacterium responsible for a patient’s infection. That bacterial isolate is then exposed to phages from a collection or phage bank to identify phages capable of infecting and killing it.

A patient may receive:

• one carefully selected phage;
• several phages combined into a cocktail; or
• occasionally a treatment that is modified as bacterial susceptibility changes.

Personalization creates an unusual regulatory and logistical challenge. Traditional medicines are manufactured as standardized products and given to many patients. Some phage therapies instead resemble a matching system in which a biological treatment is selected for a particular patient’s bacterial strain.

FDA specifically identifies personalized phage cocktails as an example of individualized therapeutics being investigated for antibiotic-resistant infections. (U.S. Food and Drug Administration, 2024)

9. Can bacteria become resistant to phages?

Yes.

Bacteria can resist phages by:

• changing or losing the surface receptor used by the phage;
• preventing phage DNA from entering;
• destroying incoming phage genetic material;
• using CRISPR-Cas or other antiviral defense systems; or
• developing other resistance mechanisms.

Resistance is therefore a major consideration in phage therapy.

Strategies to reduce or manage resistance include:

• using multiple phages in a cocktail;
• changing phages when resistance appears;
• combining phages with antibiotics; and
• choosing phages whose receptors are bacterial structures important for virulence or antibiotic resistance.

Sometimes resistance to a phage carries a biological cost to the bacterium.

For example, a bacterium that changes a surface structure to escape a phage may become less virulent or more susceptible to certain antibiotics. Research has demonstrated such evolutionary trade-offs experimentally, although they should not be assumed to occur with every phage-bacterium combination.

10. Is phage therapy approved by regulatory agencies such as FDA or EMA?

As of 2026, there is no routinely marketed FDA-approved bacteriophage therapy for treating human bacterial infection in the United States.

Human phage treatment may instead be available through:

• clinical trials;
• Investigational New Drug (IND) protocols;
• single-patient expanded access; or
• emergency expanded-access procedures when appropriate.

FDA has reported receiving both emergency and non-emergency single-patient expanded-access IND requests for phage therapy, as well as applications for controlled clinical trials.

The European situation is also evolving.

The European Pharmacopoeia adopted General Chapter 5.31, Phage Therapy Medicinal Products, in 2024. It establishes a framework for production and quality control of phage medicinal products.

In addition, the European Medicines Agency issued a draft guideline in 2025 addressing quality requirements for bacteriophage active substances and finished medicinal products; public consultation closed in April 2026. (edqm.eu) (ema.europa.eu)

Some European countries have developed additional pathways. Belgium, for example, has pioneered a magistral-compounding approach for individualized phage preparations.

Regulation remains challenging precisely because phages can be both standardized biological products and highly individualized treatments.

11. What does the scientific evidence show about whether phage therapy works?

The answer is encouraging, though not yet definitive.

Case reports and case series include striking examples of patients with severe, difficult-to-treat infections improving after phage therapy. These cases have helped drive renewed medical interest.

Controlled clinical trials present a more complicated picture.

A systematic review of clinical trials found that modern trials generally supported safety but that convincing efficacy was demonstrated in only a minority of efficacy trials included in that review. The authors emphasized a basic therapeutic requirement: the right phage must reach the right susceptible bacterium in adequate quantities at the right location. (Stacey et al., 2022)

More recent systematic reviews likewise emphasize that clinical studies remain heterogeneous in organisms, infection sites, routes of administration, products, dosing, and study design.

Case reports therefore provide important evidence that phage therapy can work under some circumstances, but they cannot by themselves tell us how reliably it works across a broader patient population.

Larger, carefully designed trials remain essential.

12. Can phage therapy be combined with antibiotics?

Yes, and combination treatment is one of the most active areas of phage research.

Some phage-antibiotic combinations show phage-antibiotic synergy, meaning the combination performs better than either treatment alone.

Possible reasons include:

• antibiotics changing bacterial shape or physiology in ways that enhance phage replication;
• phages disrupting biofilms and improving antibiotic penetration;
• treatment with one agent making bacteria more susceptible to the other; and
• two different antimicrobial pressures reducing the chance that resistant bacteria will survive.

However, synergy should not be assumed.

Some combinations are merely additive, some show no additional benefit, and some may even be antagonistic. For example, an antibiotic that stops bacterial protein synthesis may sometimes interfere with a phage that needs an actively functioning bacterial cell to reproduce.

The particular phage, bacterium, antibiotic, dose, timing, and sequence may therefore matter. Recent reviews identify phage-antibiotic antagonism as an important knowledge gap. (pmc.ncbi.nlm.nih.gov)

13. How long does treatment take, and what results can patients expect?

There is no standard treatment duration.

Therapy may last days, weeks, or sometimes longer, depending on:

• the infection;
• organism;
• patient’s condition;
• route of administration;
• response to treatment;
• whether surgery or source control is required;
• antibiotic therapy;
• development of phage resistance; and
• immune responses to the phage.

An important point is that microbiologic improvement and clinical improvement are not always the same thing.

A reduction in bacterial numbers does not necessarily mean that a chronic wound, infected prosthesis, or osteomyelitis has been cured.

Conversely, complete bacterial eradication may not always be necessary for meaningful clinical improvement.

Patients considering phage therapy should therefore avoid assuming that published success stories predict their own outcome.

14. Who might be a candidate for phage therapy, and how can patients access it?

In the United States, patients considered for experimental phage therapy often have:

• a serious bacterial infection;
• an organism resistant to multiple antibiotics;
• a persistent or recurrent infection despite appropriate treatment; or
• limited conventional treatment options.

However, candidacy also depends on whether the patient’s bacterium can be isolated and whether an active phage can be found.

A treating physician normally needs to be involved. Possible pathways include:

• enrollment in a clinical trial;
• referral to a specialized center;
• collaboration with a laboratory or phage bank; or
• FDA expanded-access procedures.

FDA’s expanded-access pathway is not equivalent to approval of the treatment. Rather, it allows use of an investigational product in an individual patient under specified circumstances and regulatory oversight.

15. What challenges remain before phage therapy can become widely available?

Several important problems remain.

Phage matching: A useful phage must be found rapidly enough to matter clinically.

Susceptibility testing: Unlike antibiotic susceptibility testing, phage susceptibility testing is not yet standardized to the same extent across laboratories.

Manufacturing: Therapeutic phages must be produced consistently and purified from the bacteria in which they were grown.

Quality control: Identity, potency, purity, sterility, endotoxin levels, stability, and genomic characteristics need to be documented.

Resistance: Bacteria can become phage-resistant.

Pharmacology: Scientists still need better ways to predict dosing, distribution, clearance, and activity within the body.

Immune responses: Patients may develop antibodies capable of neutralizing administered phages.

Clinical evidence: Larger, well-designed trials are needed.

Regulation: Conventional pharmaceutical regulation was largely designed around fixed products, whereas personalized phage therapy may require rapid substitution or modification of phages.

Economics and intellectual property: Naturally occurring and frequently modified phage collections create business and intellectual-property challenges that differ from conventional drugs.

Recent European regulatory work reflects how seriously these manufacturing and quality questions are now being addressed. (ema.europa.eu)

16. What is the difference between lytic and temperate phages, and why does it matter?

This is one of the most important distinctions in therapeutic phage biology.

A lytic phage infects a bacterial cell, reproduces, and destroys the cell as part of its usual life cycle.

A temperate phage has another option. Instead of immediately destroying the bacterium, its genetic material may become integrated into or otherwise maintained with the bacterial genome. The infected bacterium can then survive and reproduce while carrying the phage genetic material. This state is called lysogeny.

That creates several concerns for therapy.

Temperate phages can sometimes alter bacterial characteristics and may transfer genes between bacteria. Certain phages in nature carry genes associated with bacterial toxins or other traits that would obviously be undesirable in a therapeutic product.

For this reason, conventional phage-therapy development generally favors well-characterized obligately lytic phages.

Genome sequencing is an important part of determining whether a candidate phage has genetic characteristics appropriate for therapeutic use.

17. What is phage susceptibility testing, and why is matching a phage difficult?

Phage susceptibility testing asks a question similar to antibiotic susceptibility testing:

Will this particular treatment kill this particular patient’s bacterium?

The patient’s bacterial isolate is exposed to one or more candidate phages. Laboratories may evaluate plaque formation, bacterial growth inhibition, efficiency of plating, killing curves, or other measures.

However, phage susceptibility testing is more complicated than simply observing whether a clear spot appears on a bacterial lawn.

A phage might damage bacteria without completing productive replication. Laboratory conditions can affect apparent susceptibility. Different laboratories may use different methods and interpret results differently.

A phage that performs well in a laboratory also may not necessarily perform equally well in a patient’s body.

Phage susceptibility testing is therefore an important area of standardization research. FDA and NIAID have specifically highlighted development of such testing as part of clinical phage-therapy development.

Rapid matching is particularly important for seriously ill patients: an exquisitely matched treatment is of little value if identifying and manufacturing it takes longer than the patient’s clinical condition permits.

18. Can phages treat bacteria living in biofilms?

Potentially . . . but this claim needs qualification.

A biofilm is a structured bacterial community surrounded by a protective extracellular matrix. Biofilms commonly develop on chronic wounds, prosthetic joints, catheters, orthopedic hardware, and other surfaces.

Biofilm-associated bacteria can be especially difficult to treat because:

• antibiotics may penetrate poorly;
• bacterial metabolism may be slowed;
• resistant or tolerant subpopulations may persist; and
• the surrounding matrix can protect the organisms.

Some bacteriophages can infect bacteria within biofilms. Certain phages also produce depolymerases or other enzymes capable of degrading components of capsules or biofilm matrices.

This has made phages particularly attractive for device-related and chronic infections.

However, not every phage penetrates every biofilm, and much of the strongest evidence remains experimental or based on clinical case reports rather than large randomized trials.

A 2024 review of biofilm-related infections concluded that laboratory results and clinical reports are encouraging but emphasized the need for stronger clinical trials. (pmc.ncbi.nlm.nih.gov)

Phages should therefore be described as having potential advantages against some biofilms, rather than as universally able to penetrate or eradicate them.

19. Can a patient’s immune system interfere with phage therapy?

Yes.

Although bacteriophages do not infect human cells, the human immune system can recognize them.

After repeated or prolonged exposure, a patient may produce anti-phage antibodies. Some of these antibodies can neutralize the phage, reducing its ability to infect bacteria.

The body can also remove circulating phages through organs and immune mechanisms, affecting how long an intravenously administered phage remains available.

The significance varies considerably among patients and phages.

FDA-sponsored research has demonstrated another layer of complexity: host immunity and the surrounding microbiome can influence whether phage treatment succeeds. FDA researchers, for example, have reported that phage-specific immunity can impair efficacy in experimental models of vancomycin-resistant Enterococcus. (fda.gov)

This helps explain why laboratory susceptibility alone cannot completely predict clinical success.

Future treatment strategies may need to consider not just the phage and bacterium, but also the patient’s immune system and microbiome.

20. What are engineered phages, phage cocktails, and other next-generation phage therapies?

Traditional phage therapy selects naturally occurring phages that can kill a patient’s bacterial pathogen.

Newer approaches are expanding beyond that model.

A phage cocktail contains several phages. Cocktails may increase the range of bacterial strains covered and reduce the probability that resistance to one phage will cause the entire treatment to fail.

Researchers are also developing engineered phages whose genetic material has been modified to improve characteristics such as bacterial targeting or antimicrobial activity.

Other approaches use phage-derived products rather than intact phages. These include enzymes such as:

• endolysins, which break bacterial cell walls; and
• depolymerases, which can degrade bacterial capsules or extracellular polysaccharides.

Researchers are also investigating phages as delivery systems for genetic tools, including CRISPR-based mechanisms designed to selectively damage or eliminate particular bacteria.

These approaches may eventually produce therapies that combine the specificity of phages with greater standardization and control.

At the same time, increasingly engineered products create additional questions involving safety, manufacturing, regulation, resistance, and environmental effects.

Phage therapy is therefore developing in two directions at once: more personalized treatment using rapidly matched natural phages, and more standardized or engineered phage-based medicines designed for broader populations.

REFERENCES

European Directorate for the Quality of Medicines & HealthCare. (2024). Phage therapy medicinal products (5.31): European Pharmacopoeia general chapter.
European Pharmacopoeia announcement and chapter information

European Medicines Agency. (2025). Guideline on quality aspects of phage therapy medicinal products. Draft guideline, EMA/CHMP/BWP/1/2024.
EMA phage-therapy quality guideline

Fang, Q., Yin, X., He, Y., et al. (2024). Safety and efficacy of phage application in bacterial decolonisation: A systematic review. The Lancet Microbe, 5(5), e489-e499. https://doi.org/10.1016/S2666-5247(24)00002-8.
PubMed record

Litvak, Y., et al. [Reference to be selected according to final biofilm literature set.] Biofilm-related phage therapy literature.

Stacey, H. J., De Soir, S., & Jones, J. D. (2022). The safety and efficacy of phage therapy: A systematic review of clinical and safety trials. Antibiotics, 11(10), 1340. https://doi.org/10.3390/antibiotics11101340.
PubMed record and full-text links

U.S. Food and Drug Administration. (2021). FDA and NIAID: Science and regulation of bacteriophage therapy workshop. Center for Biologics Evaluation and Research.
FDA workshop materials

U.S. Food and Drug Administration. (2024). Individualized therapeutics and precision medicine. FDA Regulatory Science Report.
FDA individualized-therapeutics page

U.S. Food and Drug Administration. (2024). Identification of targets for development of vaccines and biological therapies against gastrointestinal pathogens. Center for Biologics Evaluation and Research.
FDA bacteriophage research program

Vestby, L. K., et al. (2024). Efficacy and experience of bacteriophages in biofilm-related infections.
Open-access full text in PubMed Central